IN VIVO EVALUATION OF ANTIDIABETIC ACTIVITY WITH CO- ADMINISTRATION OF IPOMOEA QUAMOCLIT AND METFORMIN

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycaemia, which may lead to metabolic disturbances and tissue injury. The present study evaluated the antidiabetic potential of the hydroethanolic leaf extract of *Ipomoea quamoclit* L. (HAIQ), administered alone and in combination with metformin, in streptozotocin (STZ)-induced diabetic and dexamethasone-induced insulin-resistant Wistar rats. The extract was subjected to preliminary phytochemical screening, gas chromatography–mass spectrometry (GC–MS) analysis, and an in-vitro α-amylase inhibition assay. The extraction yielded 7 g of extract from 80 g of powdered leaves (8.75% w/w). Phytochemical screening revealed the presence of alkaloids, glycosides, steroids, tannins, flavonoids, carbohydrates, and amino acids, while GC–MS analysis identified 63 chromatographic peaks, including several tentatively identified phytoconstituents. HAIQ demonstrated concentration-dependent α-amylase inhibitory activity, with inhibition increasing from 8.62% at 20 µg/mL to 66.09% at 100 µg/mL and an IC₅₀ value of 78.85 µg/mL, compared with 50.80 µg/mL for acarbose. In the STZ-induced diabetic model, 28-day oral treatment with HAIQ (400 mg/kg) reduced fasting blood glucose to 145 mg/dL, compared with 212 mg/dL in diabetic control rats. The combination of HAIQ (400 mg/kg) and metformin (50 mg/kg) produced a greater reduction, with fasting blood glucose reaching 98 mg/dL, compared with 126 mg/dL in the metformin-treated group. In the dexamethasone-induced model, the combination treatment reduced blood glucose to 108 mg/dL, compared with 216 mg/dL in the model control group. Improvements in serum AST and ALT levels and qualitative pancreatic histological findings were also observed in the treated groups. These findings suggest that Ipomoea quamoclit L. leaf extract possesses promising in-vitro α-amylase inhibitory and in-vivo antidiabetic potential, with the combination of HAIQ and metformin showing greater glucose-lowering effects than either treatment alone under the conditions studied. Further investigations are warranted to establish its mechanism of action, safety, and potential clinical relevance..

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-19
DOI
https://doi.org/10.5281/zenodo.24363379
Primary Topic
Natural Antidiabetic Agents Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

IN VIVO EVALUATION OF ANTIDIABETIC ACTIVITY WITH CO- ADMINISTRATION OF IPOMOEA QUAMOCLIT AND METFORMIN

Mukund Urade, Aafrin Mulla
Zenodo (CERN European Organization for Nuclear Research)
Natural Antidiabetic Agents Studies
article

IN VIVO EVALUATION OF ANTIDIABETIC ACTIVITY WITH CO- ADMINISTRATION OF IPOMOEA QUAMOCLIT AND METFORMIN

Mukund Urade, Aafrin Mulla
article en

Abstract

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycaemia, which may lead to metabolic disturbances and tissue injury. The present study evaluated the antidiabetic potential of the hydroethanolic leaf extract of *Ipomoea quamoclit* L. (HAIQ), administered alone and in combination with metformin, in streptozotocin (STZ)-induced diabetic and dexamethasone-induced insulin-resistant Wistar rats. The extract was subjected to preliminary phytochemical screening, gas chromatography–mass spectrometry (GC–MS) analysis, and an in-vitro α-amylase inhibition assay. The extraction yielded 7 g of extract from 80 g of powdered leaves (8.75% w/w). Phytochemical screening revealed the presence of alkaloids, glycosides, steroids, tannins, flavonoids, carbohydrates, and amino acids, while GC–MS analysis identified 63 chromatographic peaks, including several tentatively identified phytoconstituents. HAIQ demonstrated concentration-dependent α-amylase inhibitory activity, with inhibition increasing from 8.62% at 20 µg/mL to 66.09% at 100 µg/mL and an IC₅₀ value of 78.85 µg/mL, compared with 50.80 µg/mL for acarbose. In the STZ-induced diabetic model, 28-day oral treatment with HAIQ (400 mg/kg) reduced fasting blood glucose to 145 mg/dL, compared with 212 mg/dL in diabetic control rats. The combination of HAIQ (400 mg/kg) and metformin (50 mg/kg) produced a greater reduction, with fasting blood glucose reaching 98 mg/dL, compared with 126 mg/dL in the metformin-treated group. In the dexamethasone-induced model, the combination treatment reduced blood glucose to 108 mg/dL, compared with 216 mg/dL in the model control group. Improvements in serum AST and ALT levels and qualitative pancreatic histological findings were also observed in the treated groups. These findings suggest that Ipomoea quamoclit L. leaf extract possesses promising in-vitro α-amylase inhibitory and in-vivo antidiabetic potential, with the combination of HAIQ and metformin showing greater glucose-lowering effects than either treatment alone under the conditions studied. Further investigations are warranted to establish its mechanism of action, safety, and potential clinical relevance..

Zenodo (CERN European Organization for Nuclear Research)
Natural Antidiabetic Agents Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon